The University of Queensland (UQ) in Australia has partnered with the university’s Queensland Brain Institute and Abbott Neuromodulation to develop a remote care platform. The platform contains a wireless neuro-stimulator that treats various conditions such as Parkinson’s disease, chronic depression, and other psychiatric conditions.

In 2021, 14.7% of the population in the US who were diagnosed with Parkinson’s disease were considered to have advanced Parkinson’s disease. That number is expected to grow to 16.1% by 2030. Additionally, 7% of the US population was diagnosed with major depressive disorder as of 2021. and Abbott Neuromodulation’s device could be helpful in handling the rise in neurological conditions.

Using this remote care platform, patients will be able to access care from anywhere in the world, and their healthcare professionals will have the ability to monitor them remotely. Healthcare professionals will also be able to treat patient symptoms in real-time, and the device has the ability for adjustment, based on treatment. This platform will allow for data-driven clinical decisions and will ultimately promote more personalized treatment.

Since this device is remote and wireless, it has the capacity to help patients who live in rural or hard-to-reach communities. People in these communities do not have easy access to medical care because of their location, but this device could allow them to access the same level of care as people in more urban communities.

The developers began working on this system prior to the Covid-19 pandemic and finalized it in October 2021. Since then, the device has received a Conformitè Europëenne (CE) Mark and FDA approval.